Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT04529876
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Tofacitinib — DRUG
    Tofacitinib claim is used as the reference group.
  • Abatacept — DRUG
    Abatacept claim is used as the exposure group.

Study Details

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Key Dates

Start date
Aug 17, 2020
Status verified
Nov 2021
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021

Study Design

Enrollment
29,464 participants (actual)

Arms

  • Arm: Tofacitinib
    Reference group
  • Arm: Abatacept
    Exposure group

Primary Outcome Measure

Time to dementia onset [ Time Frame: Through study completion (a median of 231 days) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02120-

Find similar trials in Boston, MA

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Brigham and Women's Hospital· Boston, MA

Related Studies